|
|
PROTACs’ Design of Tumor-targeting Inhibitors and Their Use in the Development of New Anti-tumor Drugs |
LI Jingqi,WU Dingyu,TAN Rui**() |
College of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China |
|
|
Abstract Abnormal protein expression often leads directly or indirectly to the development of cancer. Currently, small-molecule inhibitors that target specific proteins are widely used in tumor therapy. However, small-molecule inhibitors have problems such as susceptibility to drug resistance, limited range of target proteins, and high toxicity, which limit their clinical application. As a result, proteolysis-targeting chimaera technology has emerged. Proteolysis targeting chimaeras (PROTACs) are a type of synthetic small-molecule compound consisting of target protein ligand, linker and E3 ubiquitin ligase ligand. It can use the human body’s own ubiquitin-proteasome system (UPS) to ubiquitinate and degrade the target protein, which to some extent solves the problem of drug resistance caused by overuse of small-molecule inhibitors, and has the advantage of low toxicity. Therefore, this review has summarized the design and application of PROTACs developed by using existing small-molecule inhibitors in the field of cancer, based on the top five cancers with the highest incidence rate in China, with the aim of giving inspiration to new drug researchers, expanding the use of small-molecule targeted inhibitors, and breaking through the selection of drugs that are difficult to become drug sites.
|
Received: 28 May 2023
Published: 03 April 2024
|
|
|
|
[1] |
Jung K W, Won Y J, Kong H J, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Research and Treatment, 2018, 50(2): 303-316.
doi: 10.4143/crt.2018.143
|
|
|
[2] |
Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2021. CA: A Cancer Journal for Clinicians, 2021, 71(1): 7-33.
doi: 10.3322/caac.v71.1
|
|
|
[3] |
Boddy A M. The need for evolutionary theory in cancer research. European Journal of Epidemiology, 2023, 38(12): 1259-1264.
doi: 10.1007/s10654-022-00936-8
|
|
|
[4] |
Saadet E D, Tek I. Evaluation of chemotherapy-induced cutaneous side effects in cancer patients. International Journal of Dermatology, 2022, 61(12): 1519-1526.
doi: 10.1111/ijd.v61.12
|
|
|
[5] |
Hu M X, Li Y J, Li J X, et al. Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers. European Journal of Medicinal Chemistry, 2022, 244: 114775.
doi: 10.1016/j.ejmech.2022.114775
|
|
|
[6] |
Wang Y, Jiang X Y, Feng F, et al. Degradation of proteins by PROTACs and other strategies. Acta Pharmaceutica Sinica B, 2020, 10(2): 207-238.
doi: 10.1016/j.apsb.2019.08.001
pmid: 32082969
|
|
|
[7] |
Zou Y T, Ma D H, Wang Y Y. The PROTAC technology in drug development. Cell Biochemistry and Function, 2019, 37(1): 21-30.
doi: 10.1002/cbf.3369
pmid: 30604499
|
|
|
[8] |
Shi C C, Zhang H P, Wang P L, et al. PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis. Cell Death & Disease, 2019, 10: 815.
|
|
|
[9] |
Frost J, Galdeano C, Soares P, et al. Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition. Nature Communications, 2016, 7: 13312.
doi: 10.1038/ncomms13312
pmid: 27811928
|
|
|
[10] |
Fischer E S, Böhm K, Lydeard J R, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature, 2014, 512: 49-53.
doi: 10.1038/nature13527
|
|
|
[11] |
Flygare J A, Beresini M, Budha N, et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). Journal of Medicinal Chemistry, 2012, 55(9): 4101-4113.
doi: 10.1021/jm300060k
pmid: 22413863
|
|
|
[12] |
Sun Y H, Zhao X W, Ding N, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Research, 2018, 28: 779-781.
doi: 10.1038/s41422-018-0055-1
pmid: 29875397
|
|
|
[13] |
Shibata N, Nagai K, Morita Y, et al. Development of protein degradation inducers of androgen receptor by conjugation of androgen receptor ligands and inhibitor of apoptosis protein ligands. Journal of Medicinal Chemistry, 2018, 61(2): 543-575.
doi: 10.1021/acs.jmedchem.7b00168
pmid: 28594553
|
|
|
[14] |
Han X, Zhao L J, Xiang W G, et al. Strategies toward discovery of potent and orally bioavailable proteolysis targeting Chimera degraders of androgen receptor for the treatment of prostate cancer. Journal of Medicinal Chemistry, 2021, 64(17): 12831-12854.
doi: 10.1021/acs.jmedchem.1c00882
pmid: 34431670
|
|
|
[15] |
Cao C G, Yang J, Chen Y, et al. Discovery of SK-575 as a highly potent and efficacious proteolysis-targeting Chimera degrader of PARP 1 for treating cancers. Journal of Medicinal Chemistry, 2020, 63(19): 11012-11033.
doi: 10.1021/acs.jmedchem.0c00821
|
|
|
[16] |
Jiang X Y, Zhou J T, Wang Y, et al. PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases. European Journal of Medicinal Chemistry, 2021, 210: 112949.
doi: 10.1016/j.ejmech.2020.112949
|
|
|
[17] |
Jin Y H, Lu M C, Wang Y, et al. Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown. Journal of Medicinal Chemistry, 2020, 63(9): 4644-4654.
doi: 10.1021/acs.jmedchem.9b02058
|
|
|
[18] |
郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析. 中国肿瘤杂志, 2023, 45(3):212-220.
doi: 10.3760/cma.j.cn112152-20220922-00647
pmid: 36944542
|
|
|
[18] |
Zheng R S, Zhang S W, Sun K X, et al. Analysis of the epidemic situation of malignant tumors in China in 2016. Chin J Oncol, 2023, 45(3): 212-220.
doi: 10.3760/cma.j.cn112152-20220922-00647
pmid: 36944542
|
|
|
[19] |
Nicholson A G, Tsao M S, Beasley M B, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. Journal of Thoracic Oncology, 2022, 17(3): 362-387.
doi: 10.1016/j.jtho.2021.11.003
|
|
|
[20] |
Uribe M L, Marrocco I, Yarden Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers, 2021, 13(11): 2748.
|
|
|
[21] |
Burslem G M, Smith B E, Lai A C, et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chemical Biology, 2018, 25(1): 67-77.e3.
doi: S2451-9456(17)30353-7
pmid: 29129716
|
|
|
[22] |
Simanshu D K, Nissley D V, McCormick F. RAS proteins and their regulators in human disease. Cell, 2017, 170(1): 17-33.
doi: S0092-8674(17)30650-5
pmid: 28666118
|
|
|
[23] |
Uprety D, Adjei A A. KRAS: from undruggable to a druggable cancer target. Cancer Treatment Reviews, 2020, 89: 102070.
doi: 10.1016/j.ctrv.2020.102070
|
|
|
[24] |
Yang F, Wen Y L, Wang C F, et al. Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC. European Journal of Medicinal Chemistry, 2022, 230: 114088.
doi: 10.1016/j.ejmech.2021.114088
|
|
|
[25] |
Sun N, Ren C W, Kong Y, et al. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. European Journal of Medicinal Chemistry, 2020, 193: 112190.
doi: 10.1016/j.ejmech.2020.112190
|
|
|
[26] |
Khan S, Zhang X, Lv D W, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nature Medicine, 2019, 25: 1938-1947.
doi: 10.1038/s41591-019-0668-z
|
|
|
[27] |
Lu J, Qian Y M, Altieri M, et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chemistry & Biology, 2015, 22(6): 755-763.
doi: 10.1016/j.chembiol.2015.05.009
|
|
|
[28] |
Zhou C, Fan Z S, Zhou Z H, et al. Discovery of the first-in-class agonist-based SOS 1 PROTACs effective in human cancer cells harboring various KRAS mutations. Journal of Medicinal Chemistry, 2022, 65(5): 3923-3942.
doi: 10.1021/acs.jmedchem.1c01774
|
|
|
[29] |
Liu J Y, Xue L, Xu X, et al. FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer. Experimental Cell Research, 2021, 408(2): 112868.
|
|
|
[30] |
Alabi S, Jaime-Figueroa S, Yao Z, et al. Mutant-selective degradation by BRAF-targeting PROTACs. Nature Communications, 2021, 12: 920.
doi: 10.1038/s41467-021-21159-7
pmid: 33568647
|
|
|
[31] |
Bai L C, Zhou H B, Xu R Q, et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell, 2019, 36(5): 498-511.e17.
doi: 10.1016/j.ccell.2019.10.002
|
|
|
[32] |
Wang M L, Lu J F, Wang M, et al. Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein. Journal of Medicinal Chemistry, 2020, 63(14): 7510-7528.
doi: 10.1021/acs.jmedchem.0c00471
pmid: 32437146
|
|
|
[33] |
Hajmirza A, Emadali A, Gauthier A, et al. BET family protein BRD4: an emerging actor in NFκB signaling in inflammation and cancer. Biomedicines, 2018, 6(1): 16.
|
|
|
[34] |
Hines J, Lartigue S, Dong H Q, et al. MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53. Cancer Research, 2019, 79(1): 251-262.
doi: 10.1158/0008-5472.CAN-18-2918
pmid: 30385614
|
|
|
[35] |
Qin A C, Jin H, Song Y, et al. The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells. Cell Death & Disease, 2020, 11: 805.
|
|
|
[36] |
Sonawane Y A, Taylor M A, Napoleon J V, et al. Cyclin dependent kinase 9 inhibitors for cancer therapy. Journal of Medicinal Chemistry, 2016, 59(19): 8667-8684.
pmid: 27171036
|
|
|
[37] |
Robb C M, Contreras J I, Kour S, et al. Chemically induced degradation of CDK 9 by a proteolysis targeting chimera (PROTAC). Chemical Communications, 2017, 53(54): 7577-7580.
doi: 10.1039/C7CC03879H
|
|
|
[38] |
Posternak G, Tang X J, Maisonneuve P, et al. Functional characterization of a PROTAC directed against BRAF mutant V600E. Nature Chemical Biology, 2020, 16: 1170-1178.
doi: 10.1038/s41589-020-0609-7
|
|
|
[39] |
Donoghue C, Cubillos-Rojas M, Gutierrez-Prat N, et al. Optimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation. European Journal of Medicinal Chemistry, 2020, 201: 112451.
doi: 10.1016/j.ejmech.2020.112451
|
|
|
[40] |
Wei J L, Hu J P, Wang L, et al. Discovery of a first-in-class mitogen-activated protein kinase kinase 1/2 degrader. Journal of Medicinal Chemistry, 2019, 62(23): 10897-10911.
doi: 10.1021/acs.jmedchem.9b01528
pmid: 31730343
|
|
|
[41] |
Lebraud H, Wright D J, Johnson C N, et al. Protein degradation by In-cell self-assembly of proteolysis targeting chimeras. ACS Central Science, 2016, 2(12): 927-934.
doi: 10.1021/acscentsci.6b00280
pmid: 28058282
|
|
|
[42] |
Chen L Q, Chen Y K, Zhang C Y, et al. Discovery of first-In-class potent and selective tropomyosin receptor kinase degraders. Journal of Medicinal Chemistry, 2020, 63(23): 14562-14575.
doi: 10.1021/acs.jmedchem.0c01342
pmid: 33058680
|
|
|
[43] |
Smalley J P, Adams G E, Millard C J, et al. PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes. Chemical Communications, 2020, 56(32): 4476-4479.
doi: 10.1039/d0cc01485k
pmid: 32201871
|
|
|
[44] |
Cheng J F, Li Y, Wang X, et al. Discovery of novel PDEδ degraders for the treatment of KRAS mutant colorectal cancer. Journal of Medicinal Chemistry, 2020, 63(14): 7892-7905.
doi: 10.1021/acs.jmedchem.0c00929
pmid: 32603594
|
|
|
[45] |
Christensen J G, Burrows J, Salgia R. C-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Letters, 2005, 225(1): 1-26.
doi: 10.1016/j.canlet.2004.09.044
pmid: 15922853
|
|
|
[46] |
Lee H E, Kim M A, Lee H S, et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. British Journal of Cancer, 2012, 107(2): 325-333.
doi: 10.1038/bjc.2012.237
pmid: 22644302
|
|
|
[47] |
Chen J J, Jin J M, Gu W J, et al. Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation. Cancer Science, 2023, 114(5): 1958-1971.
doi: 10.1111/cas.v114.5
|
|
|
[48] |
Mander K A, Finnie J W. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance. Australian Veterinary Journal, 2018, 96(10): 371-378.
doi: 10.1111/avj.12747
pmid: 30255577
|
|
|
[49] |
Wang X R, Wang S, Mu H X, et al. Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer. European Journal of Medicinal Chemistry, 2022, 244: 114821.
doi: 10.1016/j.ejmech.2022.114821
|
|
|
[50] |
Li H B, Wang L L, Cao F, et al. Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer. Frontiers in Pharmacology, 2022, 13: 944455.
doi: 10.3389/fphar.2022.944455
|
|
|
[51] |
Liao X M, Qian X Q, Zhang Z M, et al. ARV-825 demonstrates antitumor activity in gastric cancer via MYC-targets and G2M-checkpoint signaling pathways. Frontiers in Oncology, 2021, 11: 753119.
doi: 10.3389/fonc.2021.753119
|
|
|
[52] |
Shebl B, Ng D, Lalazar G, et al. Targeting BCL-XL in fibrolamellar hepatocellular carcinoma. JCI Insight, 2022, 7(17): e161820.
|
|
|
[53] |
Qi Z W, Yang G L, Deng T, et al. Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein. Bioorganic Chemistry, 2021, 111: 104901.
doi: 10.1016/j.bioorg.2021.104901
|
|
|
[54] |
Zhang H P, Li G Q, Zhang Y, et al. Targeting BET proteins with a PROTAC molecule elicits potent anticancer activity in HCC cells. Frontiers in Oncology, 2019, 9: 1471.
doi: 10.3389/fonc.2019.01471
pmid: 31993368
|
|
|
[55] |
Deng Y F, Yu C F, Chen L S, et al. ARV-771 acts as an inducer of cell cycle arrest and apoptosis to suppress hepatocellular carcinoma progression. Frontiers in Pharmacology, 2022, 13: 858901.
doi: 10.3389/fphar.2022.858901
|
|
|
[56] |
Shi S, Du Y, Huang L, et al. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy. Bioorganic Chemistry, 2022, 120: 105605.
doi: 10.1016/j.bioorg.2022.105605
|
|
|
[57] |
Popow J, Arnhof H, Bader G, et al. Highly selective PTK 2 proteolysis targeting chimeras to probe focal adhesion kinase scaffolding functions. Journal of Medicinal Chemistry, 2019, 62(5): 2508-2520.
doi: 10.1021/acs.jmedchem.8b01826
|
|
|
[58] |
Anderson W F, Katki H A, Rosenberg P S. Incidence of breast cancer in the United States: current and future trends. JNCI: Journal of the National Cancer Institute, 2011, 103(18): 1397-1402.
doi: 10.1093/jnci/djr257
|
|
|
[59] |
Nilsson S, Koehler K F, Gustafsson J Å. Development of subtype-selective oestrogen receptor-based therapeutics. Nature Reviews Drug Discovery, 2011, 10: 778-792.
doi: 10.1038/nrd3551
pmid: 21921919
|
|
|
[60] |
Hu J T, Hu B, Wang M L, et al. Discovery of ERD-308 as a highly potent proteolysis targeting Chimera (PROTAC) degrader of estrogen receptor (ER). Journal of Medicinal Chemistry, 2019, 62(3): 1420-1442.
doi: 10.1021/acs.jmedchem.8b01572
pmid: 30990042
|
|
|
[61] |
Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: review of results from 37, 992 patients. Cancer and Metastasis Reviews, 2015, 34(1): 157-164.
doi: 10.1007/s10555-015-9552-6
|
|
|
[62] |
Olson C M, Jiang B S, Erb M A, et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nature Chemical Biology, 2018, 14: 163-170.
doi: 10.1038/nchembio.2538
pmid: 29251720
|
|
|
[63] |
Yang J Z, Chang Y, Tien J C Y, et al. Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13. Journal of Medicinal Chemistry, 2022, 65(16): 11066-11083.
doi: 10.1021/acs.jmedchem.2c00384
pmid: 35938508
|
|
|
[64] |
Adams C M, Mitra R, Xiao Y C, et al. Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer. Cancer Discovery, 2023, 13(5): 1210-1229.
doi: 10.1158/2159-8290.CD-22-1131
|
|
|
[65] |
Li G, Lin S S, Yu Z L, et al. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. Biochemical Pharmacology, 2022, 206: 115329.
doi: 10.1016/j.bcp.2022.115329
|
|
|
[66] |
Liu Y, Zhen Y Q, Wang G, et al. Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells. European Journal of Medicinal Chemistry, 2020, 204: 112505.
doi: 10.1016/j.ejmech.2020.112505
|
|
|
[67] |
Tovell H, Testa A, Zhou H J, et al. Design and characterization of SGK3-PROTAC1, an isoform specific SGK 3 kinase PROTAC degrader. ACS Chemical Biology, 2019, 14(9): 2024-2034.
doi: 10.1021/acschembio.9b00505
|
|
|
[68] |
Zhao B S, Burgess K. TrkC-targeted kinase inhibitors and PROTACs. Molecular Pharmaceutics, 2019, 16(10): 4313-4318.
doi: 10.1021/acs.molpharmaceut.9b00673
pmid: 31512882
|
|
|
[69] |
Liu Q Y, Tu G H, Hu Y, et al. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer. European Journal of Medicinal Chemistry, 2022, 228: 114013.
doi: 10.1016/j.ejmech.2021.114013
|
|
|
[70] |
Ohoka N, Nagai K, Hattori T, et al. Cancer cell death induced by novel small molecules degrading the TACC 3 protein via the ubiquitin-proteasome pathway. Cell Death & Disease, 2014, 5(11): e1513.
|
|
|
[71] |
Dale B, Anderson C, Park K S, et al. Targeting triple-negative breast cancer by a novel proteolysis targeting Chimera degrader of enhancer of zeste homolog 2. ACS Pharmacology & Translational Science, 2022, 5(7): 491-507.
|
|
|
[72] |
Wu Y C, Xue J Q, Li J. Chemical degrader enhances the treatment of androgen receptor-positive triple-negative breast cancer. Archives of Biochemistry and Biophysics, 2022, 721: 109194.
doi: 10.1016/j.abb.2022.109194
|
|
|
[73] |
Del Mar Noblejas-López M, Nieto-Jimenez C, Burgos M, et al. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. Journal of Experimental & Clinical Cancer Research, 2019, 38(1): 383.
|
|
|
[74] |
Wang K, Dai X Y, Yu A, et al. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L 1 expression. Journal of Experimental & Clinical Cancer Research, 2022, 41(1): 289.
|
|
|
[75] |
Sakamoto K M, Kim K B, Kumagai A, et al. Protacs:chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98(15): 8554-8559.
|
|
|
[76] |
Speltz T E, Danes J M, Stender J D, et al. A cell-permeable stapled peptide inhibitor of the estrogen receptor/coactivator interaction. ACS Chemical Biology, 2018, 13(3): 676-684.
doi: 10.1021/acschembio.7b01016
pmid: 29309722
|
|
|
[77] |
Liao H W, Li X, Zhao L Z, et al. A PROTAC peptide induces durable β-catenin degradation and suppresses Wnt-dependent intestinal cancer. Cell Discovery, 2020, 6: 35.
doi: 10.1038/s41421-020-0171-1
pmid: 32550000
|
|
|
[78] |
Naganuma M, Ohoka N, Tsuji G, et al. Development of chimeric molecules that degrade the estrogen receptor using decoy oligonucleotide ligands. ACS Medicinal Chemistry Letters, 2022, 13(1): 134-139.
doi: 10.1021/acsmedchemlett.1c00629
pmid: 35059133
|
|
|
[79] |
Chen S, Li X, Li Y H, et al. Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression. Theranostics, 2022, 12(15): 6665-6681.
doi: 10.7150/thno.75444
pmid: 36185610
|
|
|
[80] |
Shao J W, Yan Y Q, Ding D L, et al. Destruction of DNA-binding proteins by programmable oligonucleotide PROTAC (O’PROTAC): effective targeting of LEF1 and ERG. Advanced Science, 2021, 8(20): e2102555.
|
|
|
[81] |
Yan Y Q, Shao J W, Ding D L, et al. 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC. Chemical Communications, 2022, 58(14): 2383-2386.
doi: 10.1039/D1CC06525D
|
|
|
[82] |
Scott D E, Rooney T P C, Bayle E D, et al. Systematic investigation of the permeability of androgen receptor PROTACs. ACS Medicinal Chemistry Letters, 2020, 11(8): 1539-1547.
doi: 10.1021/acsmedchemlett.0c00194
pmid: 32832021
|
|
|
[83] |
Lai A C, Toure M, Hellerschmied D, et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angewandte Chemie (International Ed in English), 2016, 55(2): 807-810.
doi: 10.1002/anie.v55.2
|
|
|
[84] |
Remillard D, Buckley D L, Paulk J, et al. Degradation of the BAF complex factor BRD 9 by heterobifunctional ligands. Angewandte Chemie (International Ed in English), 2017, 56(21): 5738-5743.
doi: 10.1002/anie.v56.21
|
|
|
[85] |
Hsu H T, Chen H M, Yang Z, et al. Recruitment of RNA polymerase II by the pioneer transcription factor PHA-4. Science, 2015, 348(6241): 1372-1376.
doi: 10.1126/science.aab1223
pmid: 26089518
|
|
|
[86] |
Gadd M S, Testa A, Lucas X, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nature Chemical Biology, 2017, 13: 514-521.
doi: 10.1038/nchembio.2329
pmid: 28288108
|
|
|
[87] |
Ottis P, Toure M, Cromm P M, et al. Assessing different E 3 ligases for small molecule induced protein ubiquitination and degradation. ACS Chemical Biology, 2017, 12(10): 2570-2578.
doi: 10.1021/acschembio.7b00485
|
|
|
[88] |
Békés M, Langley D R, Crews C M. PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery, 2022, 21: 181-200.
doi: 10.1038/s41573-021-00371-6
pmid: 35042991
|
|
|
[89] |
Gao J, Yang L, Lei S M, et al. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy. Science Bulletin, 2023, 68(10): 1069-1085.
doi: 10.1016/j.scib.2023.04.028
pmid: 37169612
|
|
|
[90] |
Wang W J, Zhou Q Z, Jiang T, et al. A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models. Theranostics, 2021, 11(11): 5279-5295.
doi: 10.7150/thno.55680
pmid: 33859747
|
|
|
[91] |
Tomoshige S, Nomura S, Ohgane K, et al. Discovery of small molecules that induce the degradation of huntingtin. Angewandte Chemie, 2017, 129(38): 11688-11691.
doi: 10.1002/ange.v129.38
|
|
|
[92] |
Kargbo R B. PROTAC compounds targeting α-synuclein protein for treating neurogenerative disorders: Alzheimer’s and Parkinson’s diseases. ACS Medicinal Chemistry Letters, 2020, 11(6): 1086-1087.
doi: 10.1021/acsmedchemlett.0c00192
|
|
|
[93] |
Li M X, Yang Y Q, Zhao Q Y, et al. Degradation versus inhibition: development of proteolysis-targeting chimeras for overcoming statin-induced compensatory upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Journal of Medicinal Chemistry, 2020, 63(9): 4908-4928.
doi: 10.1021/acs.jmedchem.0c00339
|
|
|
[94] |
Degorce S L, Tavana O, Banks E, et al. Discovery of proteolysis-targeting Chimera molecules that selectively degrade the IRAK3 pseudokinase. Journal of Medicinal Chemistry, 2020, 63(18): 10460-10473.
doi: 10.1021/acs.jmedchem.0c01125
pmid: 32803978
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|